This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Reich, T. Articles by Gillings, D. Search for Related Content PubMed PubMed Citation Articles by Reich, T. Articles by Gillings, D. Social Bookmarking                         What's this?

Effects of Pentoxifylline on Severe Intermittent Claudication

From the Departments of Surgery and Rehabilitation Medicine, New York University Medical Center, New York, New York

Dennis Gillings

From the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Pentoxifylline has been shown to improve treadmill walking distances under blinded, controlled conditions in patients with intermittent claudication. From the pooled data of a blinded, controlled, randomized, multicenter trial, the data from all enrolled patients with severe claudication ( < 70 m on treadmill at base line) were evaluated. The treadmill data from these more severely ill patients were analyzed separately as a "severe subset" (placebo n = 17; pentoxifylline n=21). No differences between the two treatment groups were observed in de mography, history, or baseline treadmill walking distances. The initial claudica tion distance (ICD) improved 68% over baseline with pentoxifylline and 12% with placebo (p=.012) after twenty-four weeks of treatment. A new, derived efficacy variable was developed, "minimum distance walked," which tended to minimize psychological effects on treadmill performance. Over sixteen to twenty-four weeks of treatment, the pentoxifylline group improved 49% over baseline and the placebo group 3% (p=.019), when the "minimum distance walked" measurement was used. In this controlled trial the subset of patients with severe intermittent claudication benefited from pentoxifylline therapy.

Angiology, Vol. 38, No. 9, 651-656 (1987)
DOI: 10.1177/000331978703800901


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Casey, B. H. Tonnessen, W. C. Sternbergh III, and S. R. Money Medical Management of Intermittent Claudication Vascular and Endovascular Surgery, September 1, 2004; 38(5): 391 - 399. [Abstract] [PDF]

				A. J Maxwell, B. E Anderson, and J. P Cooke Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar(R) Vascular Medicine, February 1, 2000; 5(1): 11 - 19. [Abstract] [PDF]

				D. J. Effeney, J. A. Stokes, and H. M. Trenerry The Trials and Tribulations of Pentoxifylline Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1992; 5(2): 123 - 137. [PDF]

				R. W. Schwartz, N. M. Logan, P. J. Johnson, W. E. Strodel, J. G. Fine, A. Kazmers, and G. L. Hyde Pentoxifylline Increases Extremity Blood Flow in Diabetic Atherosclerotic Patients Arch Surg, April 1, 1989; 124(4): 434 - 437. [Abstract] [PDF]